A study conducted in Japan found that recovery days can be reduced from only 14 to 11 in patients with mild to moderate condition • This treatment may help shorten the isolation period
"The study observed a rapid clinical recovery"
Photography:
AP
Corona patients in mild to moderate condition:
In a third phase study published yesterday (Thursday) in Japan, it was found that the duration of
corona
patients, in mild to moderate condition with pneumonia (as a result of the disease) was shortened by three days after treatment with Avigan FAVIPIRAVIR (200 ml tablets). C) compared to the placebo group.
Patients at Avigan had a rapid clinical recovery that manifested in improvement in cough symptoms, fever, chest X-ray findings, and penile tests were found to be free of virus traces.
Reducing the disease by 3 days from 14 sick days to 11 days is a significant statistical difference.
Due to the fact that most patients are defined as mild to moderate, the treatment could help shorten the isolation period, significantly save the length of hospitalization days and reduce the probability of developing difficult patients, in addition to reducing the workload in hospitals.
Avigan treatment was originally developed by the pharmaceutical giant FUJIFILM, JAPAN against new and unfamiliar flu strains.
The treatment approved for use in Japan in March 2014, is defined as a treatment with a high safety profile.
These days, since the outbreak of corona, treatment for this disease has been studied at the world's leading medical centers, including Stanford University, the United Kingdom (London University College), France (Bordeaux University Hospital) and more.